Washington is currently home to 1730 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Providence Regional Cancer System-Aberdeen, Aberdeen, Washington
Conditions: Multiple Myeloma
Register for Updates
EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy
NCT05476276
Recruiting
This is a Platform Protocol to perform Phase II clinical trials in The Early Phase Pain Investigation Clinical Network (EPPIC-Net), under The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, related to the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) in a platform setting to test multiple assets under a single protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: University of Washington, Seattle, Washington
Conditions: Painful Diabetic Neuropathy
Register for Updates
Comparing Two Models of Well-Child Care for Black Families
NCT05852392
Recruiting
Parent-focused Redesign for Encounters, Newborns to Toddlers (PARENT) is a team-based approach to care that utilizes a community health worker in a health educator role ("Parent's Coach") to provide many of the Well-Child Care (WCC) services that children and families should receive, addresses specific needs faced by families in low-income communities, and decreases reliance on the clinician as the primary provider of WCC services. The model was developed in partnership with clinics and parents... Read More
Gender:
ALL
Ages:
Between 9 months and 15 months
Trial Updated:
08/16/2024
Locations: Seattle Children's Research Institute, Seattle, Washington
Conditions: Pediatric, Well Child Care
Register for Updates
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
NCT06557902
Recruiting
Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
08/14/2024
Locations: Clinical Site 8, Everett, Washington
Conditions: Autism Spectrum Disorder
Register for Updates
Indian Transforming Alzheimer's Care Training (INTACT)
NCT06397339
Recruiting
INTACT will utilize a group-randomized trial, to test the effectiveness of a culturally informed provider training and "dementia friendly clinic" intervention for detection and appropriate management of AI/AN patients with ADRD and MCI in 28 urban and rural clinics serving AI/ANs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Washington State University, Seattle, Washington
Conditions: Alzheimer Disease
Register for Updates
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013
Recruiting
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Providence Regional Cancer System-Aberdeen, Aberdeen, Washington
Conditions: Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Register for Updates
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Overlake Medical Center, Bellevue, Washington
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: FHCC Overlake, Bellevue, Washington
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415
Recruiting
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: University of Washington (UW) Medical Center, Seattle, Washington
Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Register for Updates
First Face Training Evaluation in Tribal Communities
NCT05998005
Recruiting
The goal of this study is to evaluate a culturally grounded training curriculum, First Face for Mental Health, in Tribal communities, using a waitlist controlled trial design. This curriculum will train Tribal community members in how to respond to youth and adults experiencing mental health crises and serve as a bridge between these individuals and the help they need. The main questions the study aims to answer are: * Does the training increase mental health knowledge, capacity and ability to... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
08/13/2024
Locations: Kalispel Tribe of Indians, Cusick, Washington
Conditions: Mental Health, Substance-Related Disorders
Register for Updates
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy
NCT04829539
Recruiting
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2024
Locations: PeaceHealth Saint Joseph Medical Center, Bellingham, Washington
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
NCT06552611
Recruiting
Current disease-modifying therapies for multiple sclerosis (MS) aim to prevent the development of new lesions; unfortunately, no current FDA-approved therapies promote central nervous system (CNS) repair mechanisms. Thus, strategies to promote functional recovery from lesion-related deficits in adults with MS remain an unmet need. This is a pilot study designed to test the feasibility, safety and preliminary efficacy of non-invasive (transcutaneous, applied by surface electrodes over the skin)... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
08/09/2024
Locations: University of Washington, Seattle, Washington
Conditions: Multiple Sclerosis
Register for Updates